Ideaya Biosciences Inc (NASDAQ: IDYA) on Friday, plunged -0.49% from the previous trading day, before settling in for the closing price of $30.69. Within the past 52 weeks, IDYA’s price has moved between $23.41 and $47.74.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 14.24% over the past five years. The company achieved an average annual earnings per share of -27.81%. With a float of $76.56 million, this company’s outstanding shares have now reached $84.48 million.
Let’s look at the performance matrix of the company that is accounted for 124 employees. In terms of profitability, gross margin is 64.98%, operating margin of -1600.08%, and the pretax margin is -1285.34%.
Ideaya Biosciences Inc (IDYA) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Ideaya Biosciences Inc is 9.37%, while institutional ownership is 91.78%. The most recent insider transaction that took place on Aug 26 ’24, was worth 3,016,500. Before that another transaction happened on May 29 ’24, when Company’s Chief Scientific Officer sold 28,500 for $36.24, making the entire transaction worth $1,032,884. This insider now owns 0 shares in total.
Ideaya Biosciences Inc (IDYA) Performance Highlights and Predictions
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.46 earnings per share (EPS) for the period topping the consensus outlook (set at -0.49) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.64 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -27.81% per share during the next fiscal year.
Ideaya Biosciences Inc (NASDAQ: IDYA) Trading Performance Indicators
Ideaya Biosciences Inc (IDYA) is currently performing well based on its current performance indicators. A quick ratio of 17.50 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 215.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.18, a number that is poised to hit -0.64 in the next quarter and is forecasted to reach -2.84 in one year’s time.
Technical Analysis of Ideaya Biosciences Inc (IDYA)
Ideaya Biosciences Inc (NASDAQ: IDYA) saw its 5-day average volume 0.63 million, a negative change from its year-to-date volume of 0.86 million. As of the previous 9 days, the stock’s Stochastic %D was 72.05%. Additionally, its Average True Range was 1.37.
During the past 100 days, Ideaya Biosciences Inc’s (IDYA) raw stochastic average was set at 11.76%, which indicates a significant decrease from 58.73% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.49% in the past 14 days, which was higher than the 51.67% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $34.90, while its 200-day Moving Average is $39.51. Nevertheless, the first resistance level for the watch stands at $31.15 in the near term. At $31.75, the stock is likely to face the second major resistance level. The third major resistance level sits at $32.10. If the price goes on to break the first support level at $30.20, it is likely to go to the next support level at $29.85. Assuming the price breaks the second support level, the third support level stands at $29.25.
Ideaya Biosciences Inc (NASDAQ: IDYA) Key Stats
Market capitalization of the company is 2.58 billion based on 75,687K outstanding shares. Right now, sales total 23,390 K and income totals -112,960 K. The company made 0 K in profit during its latest quarter, and -39,570 K in sales during its previous quarter.
